GLP-1 receptor agonist-based therapies and cardiovascular risk: a review of mechanisms.

J Endocrinol · 2024 · PMC11466209 · PMID 39145614

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

nearly significantno p-value reported

Nonetheless, in the EXSCEL trial, once-weekly exenatide demonstrated a significant 12% reduction in all-cause mortality and nearly significant decreases in three-point MACE.

also in 3,287 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.